Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (Triwise Capital), established in Shenzhen, China in 2015, is a leading private equity investment firm that is dedicated to become the most trustworthy partner behind great corporations. Triwise Capital currently has 30 billion of RMB under management.

Triwise Capital is specialized in early stage investments in Bio-Medicine and TMT. The management team is comprised of former senior executives from China Securities Regulatory Commission, Shenzhen Stock Exchange, Shenzhen Capital Group, Guosen Securities; former industrial management from Roche Pharmaceutical, MD Anderson Cancer Center, Tencent,; and experts from top academic institutions like Pritzker School of Medicine at the University of Chicago.

Triwise Capital believes that advancing and developing together with investee enterprises is the core of investment. With a “30% Investment + 70% Service” philosophy, Triwise Capital brings value by connecting entrepreneurs with not only capital, but more importantly, essential resources that boost business development.

Over the last 5 years, Triwise Capital has utilized its professionalism, vision and acuteness to invest in and to build concrete relationships with multiple start-ups, including Immvira Pharma Co., Ltd., Akeso Biopharma Co., Ltd., Transwarp, and Sanmeng Tech.

勤智生态 | FDA四条“特别审批通道” 详解，冠科美博新药获得CDE拟突破性疗法认定